DiaMedica Therapeutics Announces Expansion Of DM199 Program Into Preeclampsia

6/26/24 8:01:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DMAC alert in real time by email

Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024
Key Proof-of-Concept Results Expected in the First Half of 2025
Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Discuss Preeclampsia
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia. Preeclampsia is a life-threatening pregnancy-associated vascular disorder characterized by new onset hypertension with proteinuria, and/or end organ dysfunction, and poses significant risks to both mother and baby. There are no approved therapeutics for preeclampsia in the U.S. or Europe.

Get the next $DMAC alert in real time by email

Date	Price Target	Rating	Analyst
10/7/2024	$7.00	Buy	H.C. Wainwright
4/24/2024	$8.00	Buy	Craig Hallum
6/22/2023	$7.00	Perform → Outperform	Oppenheimer
6/30/2021	$38.00 → $32.00	Buy	Roth Capital

DiaMedica Therapeutics Announces Expansion Of DM199 Program Into Preeclampsia

Chat with this insight

Recent Analyst Ratings for $DMAC

$DMAC Financials

Live finance-specific insights

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

$DMAC Press Releases

Fastest customizable press release news feed in the world

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

$DMAC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

SEC Form 4 filed by Wambeke David J.

$DMAC Leadership Updates

Live Leadership Updates

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

$DMAC SEC Filings

$DMAC Large Ownership Changes

This live feed shows all institutional transactions in real time.

$DMAC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$DMAC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 10-Q filed by DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

DiaMedica Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

$DMAC Market Insights

Live Market Insights

DiaMedica Therapeutics Releases Preeclampsia White Paper And Announces Key Opinion Leader Webinar On DM199 For The Treatment Of Preeclampsia

DiaMedica Therapeutics Files For Resale Of Up To 4.7M Common Shares By The Selling Shareholders

DiaMedica Therapeutics shares are trading higher. The company announced a $11.8 million private placement and will issue 4.720 million shares at $2.50 per share.

Recent Analyst Ratings for
$DMAC

$DMAC
Financials

$DMAC
Press Releases

$DMAC
Insider Trading

$DMAC
Leadership Updates

$DMAC
SEC Filings

$DMAC
Large Ownership Changes

$DMAC
Analyst Ratings

$DMAC
Insider Purchases

$DMAC
Market Insights